Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04039087 · ClinicalTrials.gov registry record · Phase 2
Sildenafil Exercise: Role of PDE5 Inhibition
A Phase 2 study, sponsored by National Jewish Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT04039087 is a Phase 2 study that has completed, run by National Jewish Health. The registered enrollment target is 26 participants.
The verdict
NCT04039087, a Phase 2 study, has completed, sponsored by National Jewish Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
Exercise intolerance is an understudied phenomenon in people with CF. The investigators hypothesized that vascular dysfunction plays a significant role, and can be partially reversed by administration of the phosphodiesterase type 5 (PDE5) inhibitor, sildenafil.
Interventions
- DRUG Sildenafil 40mg oral capsule
- DRUG Placebo Oral capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2019-09-05 |
| Est. Completion | 2024-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04039087
The ClinicalTrials.gov registry entry for NCT04039087 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Jewish Health, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sildenafil 40mg oral capsule is the first listed.
NCT04039087 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04039087 about?
NCT04039087 is a clinical study titled "Sildenafil Exercise: Role of PDE5 Inhibition". Exercise intolerance is an understudied phenomenon in people with CF. The investigators hypothesized that vascular dysfunction plays a significant role, and can be partially reversed by administration of the phosphodiesterase type 5 (PDE5) inhibitor, sildenafil.
What is the current status of trial NCT04039087?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2019-09-05. Estimated completion is 2024-06-30.
What interventions are being tested in trial NCT04039087?
The interventions under investigation include: Sildenafil 40mg oral capsule (DRUG), Placebo Oral capsule (DRUG).
Who is sponsoring clinical trial NCT04039087?
This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.